

A nutritional supplement for better breastfeeding?

Submission date 16/07/2020	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 28/10/2020	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 30/12/2022	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Breastfeeding has health benefits for both mother and baby. Women who develop diabetes in pregnancy (also known as gestational diabetes) have a higher chance of developing Type 2 diabetes in later life. Breastfeeding reduces this risk. Women who have diabetes in pregnancy are more likely to have problems with lower levels of breastmilk being made and this is a common reason for stopping breastfeeding in Ireland. Fenugreek is a herb used in Asian cooking. It is used in traditional medicine to treat diabetes. It is often recommended to improve the amount of breastmilk being made. The aim of this study is to test whether fenugreek can improve the amount of breastmilk being made in women who had a pregnancy with gestational diabetes. The researchers also want to find out if it works by changing the way the woman's body responds to the levels of glucose or sugar in the blood.

Who can participate?

Pregnant women with diabetes in pregnancy, after they have given birth

What does the study involve?

The study will involve taking a one-month supply of fenugreek capsules. The researchers will take some measurements of the mothers and babies in the postnatal ward. They will measure their weight and height and check the baby's weight, length and head measurement. Mothers will have a blood test after they deliver to check their blood glucose/sugar level while they are fasting. The researchers will show them how to weigh their baby before and after every feed, for 24 hours. This allows them to measure how much milk the baby has had in those 24 hours. The researchers will do this during the mothers' time in hospital after they give birth. This weighing will be repeated for another 24 hours, after the 28 days of taking the supplement. Mothers will be given weighing scales for this, which will be collected after the study. The researchers will also ask them to provide a small sample of breastmilk at the end of the study. Mothers will come back to the hospital at 6 weeks after delivery for their glucose test as normal. The researchers will take one extra blood sample at this visit. Mothers will also be asked to give a short telephone interview, where the researchers will ask about their experience of taking part in the study.

What are the possible benefits and risks of participating?

The mothers might benefit from participating but this is not guaranteed. The idea is that the supplement will help them make more breastmilk, which may help them breastfeed their child. The researchers hope to gain knowledge which will benefit future medical care as well. If this study shows that taking a daily fenugreek supplement while breastfeeding results in a more breastmilk production then this may be a safe way to improve the amount of breastmilk being produced in women at risk of low breastmilk production in the future. Mothers may find that remembering to take the supplement twice a day for 28 days, providing a breastmilk sample and completing the weighing of your baby before and after every breastfeed for 2 days inconvenient. Providing the additional blood sample at the start and end of the study may cause mild discomfort. Fenugreek is widely used as a cooking ingredient. When taken as a supplement it generally does not cause any problems but side effects such as nausea, vomiting and diarrhoea may occur. The most common side effect is a smell of maple syrup to the urine, sweat, faeces and breastmilk. This is not harmful and will stop after you stop taking fenugreek. Mothers should not take fenugreek if they have an allergy to peanuts, chickpeas or other legumes as they may also be allergic to fenugreek.

Where is the study run from?

University College Dublin (UCD) (Ireland)

When is the study starting and how long is it expected to run for?

July 2019 to February 2022

Who is funding the study?

University College Dublin (UCD) (Ireland)

Who is the main contact?

Dr Niamh Keating

niamh.keating@ucdconnect.ie

Contact information

Type(s)

Scientific

Contact name

Dr Sharleen O'Reilly

Contact details

School of Agriculture and Food Science

Room 2.16 Science South

University College Dublin

Belfield

Dublin

Ireland

Dublin 4

+353 (0)1 716 2157

sharleen.oreilly@ucd.ie

Type(s)

Public

Contact name

Dr Niamh Keating

Contact details

UCD Perinatal Research Centre
National Maternity Hospital
65-66 Lower Mount Street
Dublin
Ireland
Dublin 2
+353 (0)16373100
niamh.keating@ucdconnect.ie

Type(s)

Scientific

Contact name

Prof Mary Higgins

Contact details

UCD Perinatal Research Centre
National Maternity Hospital
65-66 Lower Mount Street
Dublin
Ireland
Dublin 2
+353 (0)16373100
mary.higgins@ucd.ie

Type(s)

Scientific

Contact name

Dr Aifric O'Sullivan

Contact details

University College Dublin
School of Agriculture and Food Science
Science Centre
South Belfield
Dublin
Ireland
Dublin 4
+353 (0)1 7162824
aifric.osullivan@ucd.ie

Type(s)

Scientific

Contact name

Prof Fionnuala McAuliffe

Contact details

UCD Perinatal Research Centre
UCD School of Medicine
National Maternity Hospital
65-66 Lower Mount Street
Dublin
Ireland
Dublin 2
+353 (0)1 6373216
fionnuala.mcauliffe@ucd.ie

Additional identifiers**EudraCT/CTIS number**

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

Nil known

Study information**Scientific Title**

A nutritional supplement (Fenugreek) for improved breastfeeding outcomes in women at risk of low breastmilk supply

Study objectives

The nutritional supplement Fenugreek is an effective and tolerable galactagogue in women with gestational diabetes intending to breastfeed.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 23/12/2019, National Maternity Hospital Ethics Committee (Holles St, Dublin 2, Ireland; +353 (0)1 6373588; ethicsresearch@nmh.ie), ref: EC32.2019

Study design

Prospective open-label study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format

Health condition(s) or problem(s) studied

Low breast milk supply in women with gestational diabetes mellitus

Interventions

Eligible participants will be asked to take a 28-day supply of the food supplement Fenugreek. 7.5 g Fenugreek seed extract (FSE) powder provided as 938 mg 8:1 concentrated FSE. At baseline, prior to commencing treatment, the women will be asked to weigh their babies before and after every feed for a 24-hour period. This gives a measure of the amount of milk consumed by the infant in that time. This will be repeated after the treatment course. In addition, maternal and infant biometric data will be collected and a fasting glucose blood sample from the mother at baseline and after the treatment course. The woman will also complete a glucose tolerance test at 6 weeks post-partum. During the treatment phase, participants will keep a symptom diary. A sample of breastmilk will be obtained after completion of the course of supplements for transcriptome and metabolomic analysis. Metabolomic profiles will be acquired using a 600 MHz NMR spectrometer. NMR allows detection and quantification of the most abundant metabolites present in biological samples. MS coupled with liquid or gas chromatography techniques will be used to target specific groups of metabolites including but not limited to fatty acids and amino acids. The transcriptome analysis and the NMR metabolomics will inform the targeted approach for MS metabolomics. The combined use of NMR and MS techniques allows for more comprehensive coverage of the breastmilk composition. After completion of the study, participants will be asked to take place in a telephone interview to share their experience of taking part in the trial.

Intervention Type

Supplement

Primary outcome measure

1. Breast milk composition measured using metabolomics and transcriptome analysis (NMR and MS) after the supplement course (28 days)
2. Breastfeeding self-efficacy measured using Breastfeeding Self Efficacy Scale Short Form at 28 days
3. Blood biomarkers: glucose and blood lipids measured using the Randox Daytona autoanalyzer, insulin and adiponectin measured using ELISA techniques at 6 weeks postpartum

Secondary outcome measures

1. Information on breastfeeding history collected by questionnaire at the time of recruitment
2. Anthropometric measured at Day 1 postnatal:
 - 2.1. Mother: weight (kg), height (cm), calculated BMI (weight/height in metres squared)
 - 2.2. Infant: birth weight (g), length (cm), head circumference (cm) and plotted on WHO centiles (%)

3. Symptoms related to fenugreek use measured using diary at weekly intervals for 28 days
4. Compliance measured using returned pill boxes at the end of the supplement course (28 days)
5. Maternal experience interview using qualitative analysis methods at the end of the trial (28 days)

Overall study start date

08/07/2019

Completion date

28/02/2022

Eligibility

Key inclusion criteria

1. Recent pregnancy affected by gestational diabetes mellitus
2. Intention to breastfeed for at least the trial period of 4 weeks

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

50

Total final enrolment

41

Key exclusion criteria

1. Age <18
2. Pre-existing diabetes
3. Low birth weight <2.5 kg
4. Congenital anomalies
5. Low Apgar score
6. NICU admission
7. Breastfeeding not recommended e.g. maternal HIV infection

Date of first enrolment

01/09/2020

Date of final enrolment

01/02/2022

Locations

Countries of recruitment

Ireland

Study participating centre
UCD Perinatal Research Centre
UCD School of Medicine
National Maternity Hospital
65-66 Lower Mount Street
Dublin
Ireland
D02 NX40

Sponsor information

Organisation
University College Dublin

Sponsor details
Belfield
Dublin
Ireland
Dublin 4
+353 (0)1 716 2157
niamh.keating@ucd.ie

Sponsor type
University/education

Website
<http://www.ucd.ie/>

ROR
<https://ror.org/05m7pjf47>

Funder(s)

Funder type
Other

Funder Name
Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in a high impact peer-reviewed journal. The protocol is available on request.

Intention to publish date

01/12/2022

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Niamh Keating (niamh.keating@ucdconnect.ie).

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version V3		18/05/2021	No	No